117707-40-1

Basic information

• Product Name: Desmethyl Levofloxacin
• Synonyms: (3S)-9-Fluoro-2,3-dihydro-3-methyl-7-oxo-10-(1-piperazinyl)-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid;Desmethyl Levofloxacin;DN 5455;(S)-9-fluro-3-Methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid;Levofloxacin Related CoMpound A;Levofloxacin Related Compound A (25 mg) ((S)-9-fluro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid);N-DesMethyl Levofloxacin (USP RC A);Levofloxacin USP Related CoMpound A
• CAS NO: 117707-40-1
• Molecular Formula: C₁₇H₁₈FN₃O₄
• Molecular Weight: 347.3409232
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 117707-40-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 600.714°C at 760 mmHg
• Flash Point: 317.101°C
• Appearance: /
• Density: 1.517g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Aqueous Acid (Slightly, Sonicated), Aqueous Base (Slightly, Sonicated), DMSO (Sl
• PKA: 5.19±0.40(Predicted)
• BRN: 6161512
• CAS DataBase Reference: Desmethyl Levofloxacin(CAS DataBase Reference)
• NIST Chemistry Reference: Desmethyl Levofloxacin(117707-40-1)
• EPA Substance Registry System: Desmethyl Levofloxacin(117707-40-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 117707-40-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 117707-40-1 differently. You can refer to the following data:
1. A metabolite of Levofloxacin
2. Desmethyl Levofloxacin is a degradation product of levofloxacin. A levofloxacin impurity with antibacterial properties.

InChI:InChI=1/C17H18FN3O4/c1-9-8-25-16-13-10(15(22)11(17(23)24)7-21(9)13)6-12(18)14(16)20-4-2-19-3-5-20/h6-7,9,19H,2-5,8H2,1H3,(H,23,24)/t9-/m0/s1

Upstream product

• 106939-34-8 ethyl (S)-(-)-9,10-Difluoro-3-Methyl-7-Oxo-2,3-Dihydro-7H-Pyrido[1,2,3-de]-[1,4]Benzoxazine-6-Carboxylate 
• 110548-04-4 (-)-ethyl 2-<<<(R)-1-hydroxyprop-2-yl>amino>methylene>-3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate 
• 94695-50-8 ethyl 3-(2,3,4,5-tetrafkuorophenyl)-3-oxopropanoate 
• 110-85-0 piperazine 
• 100986-89-8 levofloxacin Q-acid 
• 60-29-7 diethyl ether 
• 100986-85-4 levofloxacin 

Downstream Products

• 100986-85-4 levofloxacin 
• 1422376-36-0 (S)-9-fluoro-3,7-dihydro-3-methyl-10-(4-((oxiran-2-yl)methyl)piperazin-1-yl)-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 
• 1422376-42-8 (S)-9-fluoro-3,7-dihydro-10-(4-(2-hydroxy-3-(phenylamino)propyl)piperazin-1-yl)-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 
• 1422376-41-7 (S)-10-(4-(3-(benzylamino)-2-hydroxypropyl)piperazin-1-yl)-9-fluoro-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 

Relevant articles and documents

ANTIBIOTIC RESISTANCE BREAKERS

The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C6-10 aryl, C7-13 aralkyl, C5-10 heteroaryl, C6-13 heteroaralkyl, C5-10 heterocyclyl, C6-13 heterocyclalkyl, C3-10 carbocyclyl, C4-13 carbocyclalkyl, -C(=NR')-NR'R'' or –CH2- CH=CH2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infections, such as drug-resistant bacterial infections.

Conventional and microwave-assisted synthesis of quinolone carboxylic acid derivatives

Various antibacterial fluoroquinolone compounds are synthesized by the direct amination of 7-halo-6-fluoroquinolone-3-carboxylic acids with a variety of piperazine derivatives and (4aR,7aR)-octahydro-1H-pyrrolo[3,4-b]pyridine using microwave under different reaction conditions. Solvent free high yield microwave synthesis of antibacterial fluoroquinolone compounds is convenient, rapid and environmentally friendly method.

Crystal structure-based selective targeting of the pyridoxal 5?-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement

Fluctuations in the brain levels of the neuromodulator kynurenic acid may control cognitive processes and play a causative role in several catastrophic brain diseases. Elimination of the pyridoxal 5?-phosphate dependent enzyme kynurenine aminotransferase II reduces cerebral kynurenic acid synthesis and has procognitive effects. The present description of the crystal structure of human kynurenine aminotransferase II in complex with its potent and specific primary amine-bearing fluoroquinolone inhibitor (S)-(?)-9-(4-aminopiperazin-1-yl)-8- fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-azaphenalene-5-carboxylic acid (BFF-122) should facilitate the structure-based development of cognition-enhancing drugs. From a medicinal chemistry perspective our results demonstrate that the issue of inhibitor specificity for highly conserved PLP-dependent enzymes could be successfully addressed.